Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 12/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635122 | 1.00 | HDAC2 (0.64) | HDAC2HDAC8HDAC1HDAC3HDAC6 | |
| SCHEMBL5315671 | 0.82 | MMP1 (0.71) | — | |
| SCHEMBL20251150 | 0.82 | MMP1 (0.71) | — | |
| SCHEMBL18102186 | 0.81 | HDAC2 (0.56) | HDAC2HDAC8HDAC1HDAC3HDAC6 | |
| SCHEMBL14244759 | 0.81 | HDAC2 (0.89) | HDAC2HDAC8HDAC1HDAC3HDAC6 | |
| SCHEMBL5604340 | 0.81 | HDAC2 (0.67) | HDAC2HDAC8HDAC1HDAC3HDAC6 | |
| SCHEMBL17485384 | 0.81 | AKR1B1 (0.67) | HDAC2HDAC8HDAC1HDAC3HDAC6 | |
| SCHEMBL14244525 | 0.81 | HDAC2 (0.67) | HDAC2HDAC8HDAC1HDAC3HDAC6 | |
| SCHEMBL5604342 | 0.81 | HDAC2 (0.67) | HDAC2HDAC8HDAC1HDAC3HDAC6 | |
| SCHEMBL12425729 | 0.81 | HDAC2 (0.89) | HDAC2HDAC8HDAC1HDAC3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260382-B2 | Methods of reducing virulence in bacteria | UWM RESEARCH FOUNDATION (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| WO-2013113841-A1 | NOVEL THERAPEUTIC AGENTS | EURO-CELTIQUE S.A. (LU) | 2013-08-08 | — | — | WO | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | DUKE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2011103189-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | UWM RESEARCH FOUNDATION, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC2 3/4885HDAC8 4/4885HDAC1 2/4885 |
| US-20120322769-A1 | METHODS OF REDUCING VIRULENCE IN BACTERIA | PGLS, RRS1, MRPL21 | HDAC2 4243/4885HDAC8 3068/4885HDAC1 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.